Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03460769 · ClinicalTrials.gov registry record
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
A clinical trial of Pancreatic Cancer and Chronic Pancreatitis, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 775
- Enrollment target
- 10
- Study locations
NCT03460769 is a study of Pancreatic Cancer and Chronic Pancreatitis that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 775 participants, above the 390-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (99% higher). The trial reports 10 study locations across 7 states.
The verdict
NCT03460769, a study of Pancreatic Cancer and Chronic Pancreatitis, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 775 participants
- Enrollment target
- 10
- Study locations
Study Summary
The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). Similar to all studies that will be coordinated and managed by the CDMC, no patient enrollment will occur at MDACC. All patient recruitment will occur at external sites that are a part of the CPDPC, which are listed in the appended DETECT protocol. The data management systems, auditing, and monitoring effort are supported by the CDMC.
Conditions Studied
Interventions
- OTHER Data Management and Monitoring
Study Locations (10)
California
- Cedars-Sinai Medical Center - Los Angeles
- Stanford University - Stanford
Minnesota
- University of Minnesota - Minneapolis
- Mayo Clinic - Rochester
Texas
- Baylor College of Medicine - Houston
- University of Texas MD Anderson Cancer Center - Houston
Florida
- University of Florida - Gainesville
Indiana
- Indiana University - Carmel
Ohio
- Ohio State University - Columbus
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 775 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2027-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03460769
The ClinicalTrials.gov registry entry for NCT03460769 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 775 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 390-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (99% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Data Management and Monitoring is the first listed.
NCT03460769 reports 10 study locations spanning 7 distinct geographic areas - top geographies include California, Minnesota, Texas.
Frequently Asked Questions
What is clinical trial NCT03460769 about?
NCT03460769 is a clinical study titled "Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)". The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETEC...
What is the current status of trial NCT03460769?
This trial is currently recruiting. The enrollment target is 775 participants. The study started on 2021-04-01. Estimated completion is 2027-06-30.
What conditions does trial NCT03460769 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Chronic Pancreatitis, Diabetes Mellitus Type 3c.
What interventions are being tested in trial NCT03460769?
The interventions under investigation include: Data Management and Monitoring (OTHER).
Who is sponsoring clinical trial NCT03460769?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03460769 being conducted?
This trial has 10 study locations across California, Florida, Indiana, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.